286 related articles for article (PubMed ID: 36239554)
1. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract][Full Text] [Related]
4. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
7. How we treat patients with metastatic HER2-positive breast cancer.
Nader-Marta G; Martins-Branco D; de Azambuja E
ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
[TBL] [Abstract][Full Text] [Related]
8. Systemic management of brain metastases in HER2+ breast cancer in 2022.
Alder L; Sammons S; Van Swearingen AED; Anders CK
Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.
Ferrario C; Christofides A; Joy AA; Laing K; Gelmon K; Brezden-Masley C
Curr Oncol; 2022 Apr; 29(4):2720-2734. PubMed ID: 35448196
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
[TBL] [Abstract][Full Text] [Related]
13. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
14. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
15. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
17. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Wang M; Wang K; Zhu H
Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
